On November 2, 2019, the State Drug Administration approved the application for the marketing of a new drug for the treatment of Alzheimer's disease--Nine Phase One® (Manlut sodium, code: GV-971)."Used to treat mild to moderate Alzheimer's disease and improve cognitive function in patients."
Nine Phase One® is a research team led by Prof. Meiyu Gen from the Shanghai Institute of Materia Medica, Chinese Academy of Sciences. For 22 years, The innovative drug was successfully developed by Ocean University of China, Shanghai Institute of Materia Medica and Shanghai Green Valley Pharmaceutical Co., Ltd.Nine Phase One® can significantly improve cognitive dysfunction in patients with mild to moderate Alzheimer's disease. Nine Phase One® has a fast-acting, sustained and steadily improving cognitive function, and is safe and poor. The incidence of bad events was comparable to that of the placebo group.
This unique mechanism of action targeting the brain-gut axis provides an important scientific basis for a deep understanding of the clinical efficacy of nine Phase I®.At the same time, Green Valley will start the post-marketing study of the nine Phase I® and is actively promoting the international multi-center clinical research project, hoping to benefit patients worldwide as soon as possible.
